Jaemin Jo Jung Ho Kim Ji Young Kim Changlim Hyun Jiyoung Rhee Jungmi Kwon Sanghoon Han Wookun Kim
10.4143/crt.2014.209
Cancer Res Treat
2016 Jan;48(1):393-7.
drug therapy lung neoplasms pazopanib tyrosine kinase inhibitor
CC BY-NC
https://pubmed.ncbi.nlm.nih.gov/25715772/
Carcinoma, Non-Small-Cell Lung / drug therapy Carcinoma, Non-Small-Cell Lung / secondary Carcinoma, Renal Cell / drug therapy Carcinoma, Renal Cell / pathology Kidney Neoplasms / drug therapy Lung Neoplasms / drug therapy Lung Neoplasms / secondary Pyrimidines / therapeutic use Sulfonamides / therapeutic use
Carcinoma, Non-Small-Cell Lung / drug therapy Carcinoma, Non-Small-Cell Lung / secondary Carcinoma, Renal Cell / drug therapy Carcinoma, Renal Cell / pathology Kidney Neoplasms / drug therapy Lung Neoplasms / drug therapy Lung Neoplasms / secondary Pyrimidines / therapeutic use Sulfonamides / therapeutic use Case Reports Aged Disease-Free Survival Humans Indazoles Kidney Neoplasms / pathology Male Protein-Tyrosine Kinases / antagonists & inhibitors Pyrimidines / pharmacology Republic of Korea Sulfonamides / pharmacology Treatment Outcome Indazoles Pyrimidines Sulfonamides pazopanib Protein-Tyrosine Kinases
PMC4720062
25715772
Pazopanib for Non-small Cell Lung Cancer: The First Case Report in Korea
2016